NCT04265755View on ClinicalTrials.gov

Biomarker and Genetic Predictors of Erenumab Treatment Response

PHASE4CompletedINTERVENTIONAL
Enrollment

1,406

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

January 18, 2023

Study Completion Date

January 18, 2023

Conditions
Migraine
Interventions
DRUG

Erenumab

Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).

Trial Locations (2)

101

Thjonustumidstod Rannsoknaverkefna, Reykjavik

2600

Glostrup Hospital, Glostrup Municipality

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY